Last reviewed · How we verify
continuous oral cyclophosphamide and methotrexate — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
continuous oral cyclophosphamide and methotrexate (continuous oral cyclophosphamide and methotrexate) — Grupo de Apoio ao Adolescente e a Crianca com Cancer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| continuous oral cyclophosphamide and methotrexate TARGET | continuous oral cyclophosphamide and methotrexate | Grupo de Apoio ao Adolescente e a Crianca com Cancer | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- continuous oral cyclophosphamide and methotrexate CI watch — RSS
- continuous oral cyclophosphamide and methotrexate CI watch — Atom
- continuous oral cyclophosphamide and methotrexate CI watch — JSON
- continuous oral cyclophosphamide and methotrexate alone — RSS
Cite this brief
Drug Landscape (2026). continuous oral cyclophosphamide and methotrexate — Competitive Intelligence Brief. https://druglandscape.com/ci/continuous-oral-cyclophosphamide-and-methotrexate. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab